HAMBURG, Germany, January 27 /PRNewswire-FirstCall/ -- Evotec OAI, a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, today announced that Joern Aldag, President and CEO of Evotec OAI, will present at the UBS Global Healthcare Services Conference at 09:30 a.m. ET on Wednesday, February 4 2004, at The Plaza in New York City.
The audio portion of the presentation will be a webcast via the UBS website at http://event.streamx.us/event/default.asp?Event=UBS20040202. The accompanying slides are available on request. Please e-mail to: investor.relations@evotecoai.com.
About Evotec OAI AG
Evotec OAI has established itself as the partner of choice for drug discovery and development services for pharmaceutical and biotechnology companies worldwide, maintaining its leadership role through innovation and unmatched customer service. The Company’s business strategy is clearly focussed on drug discovery. It has established the most comprehensive technology platform and skills that integrate its world-class biology and chemistry capabilities. Evotec OAI leverages this discovery engine in providing assay development and screening through to compound optimisation and drug manufacturing services to a broad and well-established network of customers. In addition, the Company engages in selected discovery programmes itself to develop drug candidates for early out-licensing. Evotec OAI’s instrument and technology business is now successfully handled by its affiliate, Evotec Technologies.
Evotec OAI AG
CONTACT: Contact: Evotec OAI AG, Anne Hennecke, tel +49-40-56081286,anne.hennecke@evotecoai.com
